List of Giazo drug patents

Giazo is owned by Valeant Pharms Intl.

Giazo contains Balsalazide Disodium.

Giazo has a total of 4 drug patents out of which 0 drug patents have expired.

Giazo was authorised for market use on 03 February, 2012.

Giazo is available in tablet;oral dosage forms.

Giazo can be used as treatment of mildly to moderately active ulcerative colitis in male patients.

The generics of Giazo are possible to be released after 23 June, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192616 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Aug, 2026

(3 years from now)

US7452872 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Aug, 2026

(3 years from now)

US7625884 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Aug, 2026

(3 years from now)

US8497256 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
Jun, 2031

(8 years from now)

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Market Authorisation Date: 03 February, 2012

Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients

Dosage: TABLET;ORAL

How can I launch a generic of GIAZO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in